Affimed Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 78

Employees

  • Stock Symbol
  • AFMDQ

Stock Symbol

  • Investments
  • 1

Affimed General Information

Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Contact Information

Website
www.affimed.com
Formerly Known As
Affimed Therapeutics AG
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Gottlieb-Daimler-Strasse second
  • 68165 Mannheim
  • Germany
+49 0621
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • Gottlieb-Daimler-Strasse second
  • 68165 Mannheim
  • Germany
+49 0621

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affimed Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
24.3K

Affimed Financials Summary

As of 30-Sep-2024, Affimed has a trailing 12-month revenue of $951K.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 30,381 12,467 (15,493) 443,688
Revenue 951 8,954 43,479 47,725
EBITDA (72,072) (111,334) (85,661) (65,588)
Net Income (75,879) (114,633) (90,425) (68,009)
Total Assets 44,630 107,397 215,029 254,903
Total Debt 14,396 21,391 19,506 21,162
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Affimed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Affimed‘s full profile, request access.

Request a free trial

Affimed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Affimed‘s full profile, request access.

Request a free trial

Affimed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted
Drug Discovery
Mannheim, Germany
78 As of 2023

Tuebingen, Germany
 

Hampton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Affimed Competitors (75)

One of Affimed’s 75 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Formerly VC-backed Tuebingen, Germany
Celldex Formerly VC-backed Hampton, NJ
Agenus Formerly VC-backed Lexington, MA
TME Pharma Formerly VC-backed Berlin, Germany
Cellectis Formerly VC-backed Paris, France
You’re viewing 5 of 75 competitors. Get the full list »

Affimed Patents

Affimed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4751734-A1 Bispecific antibody construct dosage regimen for treating nsclc Pending 29-Nov-2024
WO-2026115158-A1 Bispecific antibody construct dosage regimen for treating nsclc Pending 29-Nov-2024
EP-4751731-A1 Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane Pending 29-Nov-2024
WO-2026115137-A1 Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane Pending 29-Nov-2024
EP-4751777-A1 Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor Pending 29-Nov-2024 C07K16/2863
To view Affimed’s complete patent history, request access »

Affimed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affimed Investments (1)

Affimed’s most recent deal was a Later Stage VC with Amphivena Therapeutics for . The deal was made on 26-Jun-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amphivena Therapeutics 26-Jun-2017 Later Stage VC Biotechnology
To view Affimed’s complete investments history, request access »

Affimed ESG

Risk Overview

Risk Rating

Updated March, 31, 2023

29.65 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,942

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Biotechnology

Subindustry

of 412

Rank

Percentile

To view Affimed’s complete esg history, request access »

Affimed FAQs

  • When was Affimed founded?

    Affimed was founded in 2000.

  • Where is Affimed headquartered?

    Affimed is headquartered in Mannheim, Germany.

  • What is the size of Affimed?

    Affimed has 78 total employees.

  • What industry is Affimed in?

    Affimed’s primary industry is Drug Discovery.

  • Is Affimed a private or public company?

    Affimed is a Public company.

  • What is Affimed’s stock symbol?

    The ticker symbol for Affimed is AFMDQ.

  • What is Affimed’s current revenue?

    The trailing twelve month revenue for Affimed is $951K.

  • Who are Affimed’s competitors?

    Immatics, Celldex, Agenus, TME Pharma, and Cellectis are some of the 75 competitors of Affimed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process